Weekly Investment Analysts’ Ratings Updates for Tandem Diabetes Care (TNDM)

Several analysts have recently updated their ratings and price targets for Tandem Diabetes Care (NASDAQ: TNDM):

• 10/8/2025 – Tandem Diabetes Care had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Tandem Diabetes Care had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $15.00 price target on the stock, up previously from $11.00.
• 9/29/2025 – Tandem Diabetes Care had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $24.00 price target on the stock.
• 9/27/2025 – Tandem Diabetes Care had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/8/2025 – Tandem Diabetes Care is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $22.00 price target on the stock.
• 8/21/2025 – Tandem Diabetes Care had its price target raised by analysts at Citigroup Inc. from $10.35 to $11.00. They now have a “neutral” rating on the stock.

Insiders Place Their Bets

In other news, CEO John F. Sheridan purchased 10,000 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was acquired at an average price of $10.23 per share, for a total transaction of $102,300.00. Following the completion of the transaction, the chief executive officer directly owned 106,327 shares in the company, valued at $1,087,725.21. This represents a 10.38% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CFO Leigh Vosseller purchased 13,720 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $10.89 per share, with a total value of $149,410.80. Following the transaction, the chief financial officer owned 25,580 shares of the company’s stock, valued at approximately $278,566.20. This represents a 115.68% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.90% of the company’s stock.

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.